81 related articles for article (PubMed ID: 18990017)
1. Clinical evaluation of 5-fluorouracil from transdermal patches on EAC and DLA cell-induced tumors in mice.
Chandrashekar NS; Prasanth VV
Asian Pac J Cancer Prev; 2008; 9(3):437-40. PubMed ID: 18990017
[TBL] [Abstract][Full Text] [Related]
2. Transdermal delivery of 5-fluorouracil for induced ehrlich ascites carcinoma tumor in BALB/c mice and pharmacokinetic study.
Chandrashekar NS; Hiremath SR
Recent Pat Anticancer Drug Discov; 2007 Nov; 2(3):235-9. PubMed ID: 18221066
[TBL] [Abstract][Full Text] [Related]
3. Microprocessor-controlled iontophoretic drug delivery of 5-fluorouracil: pharmacodynamic and pharmacokinetic study.
Chandrashekar NS; Shobha Rani RH
J BUON; 2007; 12(4):529-34. PubMed ID: 18067212
[TBL] [Abstract][Full Text] [Related]
4. Preliminary evaluation of in vitro cytotoxicity and in vivo antitumor activity of Premna herbacea Roxb. in Ehrlich ascites carcinoma model and Dalton's lymphoma ascites model.
Dhamija I; Kumar N; Manjula SN; Parihar V; Setty MM; Pai KS
Exp Toxicol Pathol; 2013 Mar; 65(3):235-42. PubMed ID: 21920724
[TBL] [Abstract][Full Text] [Related]
5. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
Yoshikawa R; Kusunoki M; Yanagi H; Noda M; Furuyama JI; Yamamura T; Hashimoto-Tamaoki T
Cancer Res; 2001 Feb; 61(3):1029-37. PubMed ID: 11221829
[TBL] [Abstract][Full Text] [Related]
6. A 5-fluorouracil-loaded floating gastroretentive hollow microsphere: development, pharmacokinetic in rabbits, and biodistribution in tumor-bearing mice.
Huang Y; Wei Y; Yang H; Pi C; Liu H; Ye Y; Zhao L
Drug Des Devel Ther; 2016; 10():997-1008. PubMed ID: 27042001
[TBL] [Abstract][Full Text] [Related]
7. [Studies of 5-fluorouracil nanocapsules].
Pan WS; Hu J
Yao Xue Xue Bao; 1991; 26(4):280-5. PubMed ID: 1957674
[TBL] [Abstract][Full Text] [Related]
8. Ganoderma lucidum total triterpenes attenuate DLA induced ascites and EAC induced solid tumours in Swiss albino mice.
Smina TP; Mathew J; Janardhanan KK
Cell Mol Biol (Noisy-le-grand); 2016 Apr; 62(5):55-9. PubMed ID: 27188870
[TBL] [Abstract][Full Text] [Related]
9. Kinetic alterations induced by 5-fluorouracil in bone marrow, intestinal mucosa, and tumor.
Myers CE; Young RC; Chabner BA
Cancer Res; 1976 May; 36(5):1653-8. PubMed ID: 1268826
[TBL] [Abstract][Full Text] [Related]
10. [Antineoplastic activity of 5-fluorouracil upon transdermal adminstration using "Coletex" napkins].
Vartanian LP; Oltarzhevskaia ND; Vershinina SF; Gornaeva GF; Pustovalov IuI; Korovina MA
Vopr Onkol; 2001; 47(4):472-4. PubMed ID: 11710293
[TBL] [Abstract][Full Text] [Related]
11. Improvement in 5-fluorouracil (5-FU) and 5-fluoro-2'-deoxyuridine (FdUrd) concentration by 5-fluorouracil-polyethylene-glycol-liposomes in abdominal stop-flow: treatment of VX2 liver-tumor-bearing rabbits.
Pohlen U; Rieger H; Binnenhei M; Reszka RC; Buhr HJ; Berger G
J Chemother; 2005 Aug; 17(4):428-34. PubMed ID: 16167523
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
[TBL] [Abstract][Full Text] [Related]
13. Antitumor efficacy and amelioration of oxidative stress by Trichosanthes dioica root against Ehrlich ascites carcinoma in mice.
Bhattacharya S; Prasanna A; Majumdar P; Kumar RB; Haldar PK
Pharm Biol; 2011 Sep; 49(9):927-35. PubMed ID: 21819262
[TBL] [Abstract][Full Text] [Related]
14. Antitumor and antioxidant activity of Polyalthia longifolia stem bark ethanol extract.
Manjula SN; Kenganora M; Parihar VK; Kumar S; Nayak PG; Kumar N; Ranganath Pai KS; Rao CM
Pharm Biol; 2010 Jun; 48(6):690-6. PubMed ID: 20645743
[TBL] [Abstract][Full Text] [Related]
15. Relationship between fluorouracil systemic exposure and tumor response and patient survival.
Milano G; Etienne MC; Renée N; Thyss A; Schneider M; Ramaioli A; Demard F
J Clin Oncol; 1994 Jun; 12(6):1291-5. PubMed ID: 8201391
[TBL] [Abstract][Full Text] [Related]
16. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
17. A galactomannan polysaccharide from Punica granatum imparts in vitro and in vivo anticancer activity.
Joseph MM; Aravind SR; George SK; Varghese S; Sreelekha TT
Carbohydr Polym; 2013 Nov; 98(2):1466-75. PubMed ID: 24053828
[TBL] [Abstract][Full Text] [Related]
18. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
Bocci G; Danesi R; Di Paolo AD; Innocenti F; Allegrini G; Falcone A; Melosi A; Battistoni M; Barsanti G; Conte PF; Del Tacca M
Clin Cancer Res; 2000 Aug; 6(8):3032-7. PubMed ID: 10955781
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of 5-fluorouracil in combination with methoxyphenyl maleamic acid in murine tumors.
Indap MA; Ambaye RY
J Postgrad Med; 1991 Oct; 37(4):211-5. PubMed ID: 1841970
[TBL] [Abstract][Full Text] [Related]
20. Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers.
Ho YF; Lu WC; Chen RR; Cheng AL; Yeh KH
Anticancer Drugs; 2011 Mar; 22(3):290-8. PubMed ID: 21150775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
